Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202677 | 0.85 | TBXA2R (0.40) | TBXA2RCYP19A1CNR2CNR1ACHE | |
| SCHEMBL28565640 | 0.75 | CYP19A1 (0.48) | CYP19A1CNR2MAPTMEN1CRHBP | |
| SCHEMBL16200825 | 0.72 | MAPT (0.40) | TBXA2RCYP19A1CNR2CNR1ACHE | |
| SCHEMBL6203512 | 0.70 | TBXA2R (0.40) | TBXA2RCYP19A1CNR2CNR1ACHE | |
| SCHEMBL28946651 | 0.69 | CA12 (0.48) | TBXA2RCYP19A1CNR2MAPTMEN1 | |
| SCHEMBL6202633 | 0.69 | ALDH1A1 (0.40) | TBXA2RCYP19A1CNR1MAPTMEN1 | |
| SCHEMBL6199119 | 0.69 | NPSR1 (0.55) | CYP19A1MAPTMEN1CRHBPKMT2A | |
| SCHEMBL6200633 | 0.67 | MMP2 (0.38) | CNR2CNR1MAPTMEN1KMT2A | |
| SCHEMBL14880488 | 0.66 | KCNJ1 (0.63) | MAPTMEN1CRHBPKMT2ACRHR2 | |
| SCHEMBL6201097 | 0.66 | CNR1 (0.38) | CNR2CNR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| US-20170368085-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | LUMENA PHARMACEUTICALS LLC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | Lumena Pharmaceuticals, Inc. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. | 2014-09-18 | — | — | US | disclosed |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | Lumena Pharmaceuticals, Inc. | 2014-09-18 | — | — | US | disclosed |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | Lumena Pharmaceuticals, Inc. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130109671-A1 | Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130108573-A1 | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109671-A1 | Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130108573-A1 | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease | Lumena Pharmaceuticals, Inc. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4035/4885CYP19A1 2563/4885CNR2 3681/4885 |
| US-20170368085-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4620/4885CYP19A1 1737/4885CNR2 4747/4885 |
| US-20130109671-A1 | Bile Acid Recycling Inhibitors for Treatment of Pediatric Cholestatic Liver Diseases | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4620/4885CYP19A1 1737/4885CNR2 4747/4885 |
| US-20140243281-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4653/4885CYP19A1 1809/4885CNR2 4722/4885 |
| US-20140275090-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS AND INFLAMMATORY BOWEL DISEASE | SLC10A2, SLC10A1, ABCB11 | TBXA2R 3234/4885CYP19A1 3904/4885CNR2 3998/4885 |
| US-20140271734-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF BARRETT'S ESOPHAGUS AND GASTROESOPHAGEAL REFLUX DISEASE | SLC10A2, SLC10A1, ABCB11 | TBXA2R 2906/4885CYP19A1 4546/4885CNR2 4342/4885 |
| US-20130108573-A1 | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4035/4885CYP19A1 2563/4885CNR2 3681/4885 |
| US-20160310518-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SLC10A1, SLC10A2, ABCB11 | TBXA2R 4620/4885CYP19A1 1737/4885CNR2 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.